K P Roland1, K M D Cornett, O Theou, J M Jakobi, G R Jones. 1. Gareth R. Jones, PhD, School of Health and Exercise Sciences, University of British Columbia Okanagan, HSC240, 3333 University Way Kelowna, British Columbia, Canada, V1V 1V7; (tel) 1+250.807.8102, (fax) 1+250.807.8085, (email) gareth.jones@ubc.ca.
Abstract
BACKGROUND: Females with Parkinson's disease (PD) are at greater risk of frailty than males. Little is known about how age and disease-related characteristics influence frailty in females with PD because frailty studies often exclude persons with underlying neurological pathologies. OBJECTIVE: To determine age and disease-related characteristics that best explain physical frailty in community-dwelling females with and without PD. DESIGN AND MEASUREMENT: Correlation coefficients described relationships between PD-related characteristics and physical frailty phenotype criteria (Cardiovascular Health Study). Regression analysis identified associations between disease-related characteristics and frailty in non-PD and PD females. SETTING: Community-dwelling. PARTICIPANTS: Females with mild to moderate PD (n = 17, mean age = 66 ± 8.5 years) and non-PD (n = 18, mean age = 72 ± 13.2 years) participated. RESULTS: Daily carbidopa-levodopa dose best explained frailty in PD females (β = 0.5), whereas in non-PD females, age (β = 0.7) and comorbidity (β = 0.5) were most associated with frailty. CONCLUSIONS: Dopaminergic medication explained frailty in PD and not measures of disease progression (i.e. severity, duration). In females without PD age-related accumulation of comorbidities resulted in greater risk of frailty. This indicates dopaminergic management of PD symptoms may better reflect frailty in females with PD than disease severity or duration. These data suggest the influence of underlying frailty should be considered when managing neurological conditions. Understanding how frailty concurrently exists with PD and how these conditions progress within the aging female will facilitate future care management.
BACKGROUND: Females with Parkinson's disease (PD) are at greater risk of frailty than males. Little is known about how age and disease-related characteristics influence frailty in females with PD because frailty studies often exclude persons with underlying neurological pathologies. OBJECTIVE: To determine age and disease-related characteristics that best explain physical frailty in community-dwelling females with and without PD. DESIGN AND MEASUREMENT: Correlation coefficients described relationships between PD-related characteristics and physical frailty phenotype criteria (Cardiovascular Health Study). Regression analysis identified associations between disease-related characteristics and frailty in non-PD and PD females. SETTING: Community-dwelling. PARTICIPANTS: Females with mild to moderate PD (n = 17, mean age = 66 ± 8.5 years) and non-PD (n = 18, mean age = 72 ± 13.2 years) participated. RESULTS: Daily carbidopa-levodopa dose best explained frailty in PD females (β = 0.5), whereas in non-PD females, age (β = 0.7) and comorbidity (β = 0.5) were most associated with frailty. CONCLUSIONS: Dopaminergic medication explained frailty in PD and not measures of disease progression (i.e. severity, duration). In females without PD age-related accumulation of comorbidities resulted in greater risk of frailty. This indicates dopaminergic management of PD symptoms may better reflect frailty in females with PD than disease severity or duration. These data suggest the influence of underlying frailty should be considered when managing neurological conditions. Understanding how frailty concurrently exists with PD and how these conditions progress within the aging female will facilitate future care management.
Authors: David Sulzer; Angelo Antonini; Valentina Leta; Anna Nordvig; Richard J Smeyne; James E Goldman; Osama Al-Dalahmah; Luigi Zecca; Alessandro Sette; Luigi Bubacco; Olimpia Meucci; Elena Moro; Ashley S Harms; Yaqian Xu; Stanley Fahn; K Ray Chaudhuri Journal: NPJ Parkinsons Dis Date: 2020-08-20
Authors: A Calderón-Larrañaga; D L Vetrano; L Ferrucci; S W Mercer; A Marengoni; G Onder; M Eriksdotter; L Fratiglioni Journal: J Intern Med Date: 2018-11-22 Impact factor: 8.989
Authors: David Sulzer; Angelo Antonini; Valentina Leta; Anna Nordvig; Richard J Smeyne; James E Goldman; Osama Al-Dalahmah; Luigi Zecca; Alessandro Sette; Luigi Bubacco; Olimpia Meucci; Elena Moro; Ashley S Harms; Yaqian Xu; Stanley Fahn; K Ray Chaudhuri Journal: NPJ Parkinsons Dis Date: 2020-08-20
Authors: María Cristina Lopes Dos Santos; María Victoria Navarta-Sánchez; José Antonio Moler; Ignacio García-Lautre; Sagrario Anaut-Bravo; Mari Carmen Portillo Journal: Parkinsons Dis Date: 2020-04-28